Originally published In Press as doi:10.1074/jbc.M001002200 on May 2, 2000
J. Biol. Chem., Vol. 275, Issue 30, 22719-22727, July 28, 2000
Utilization of Oriented Peptide Libraries to Identify Substrate
Motifs Selected by ATM*
Ted
O'Neillabc,
Alison J.
Dwyerabd,
Yael
Zive,
Doug W.
Chanf,
Susan P.
Lees-Millerf,
Robert H.
Abrahame,
Jack H.
Laig,
David
Hillh,
Yossi
Shilohi,
Lewis C.
Cantleygj, and
Gary A.
Rathbunadk
From the a Center for Blood Research, Department of
Pediatrics, Children's Hospital, Harvard Medical School,
Boston, Massachusetts 02115, the i Department of Human
Genetics and Molecular Medicine, Sackler School of Medicine, Tel Aviv
University, Ramat Aviv 69978, Israel, the f Department of
Biological Chemistry, Department of Biological Sciences, University of
Calgary, Calgary AB T2N 1 N4, Canada, the e Department of
Pharmacology and Cancer Biology, Duke University,
Durham, North Carolina 27710, the g Department of Medicine,
Beth Israel Deaconess Hospital, Harvard Medical School,
Boston, Massachusetts 02115, and h Oncogene Science, Inc.,
Cambridge, Massachusetts 02142
Received for publication, February 7, 2000, and in revised form, April 26, 2000
 |
ABSTRACT |
The ataxia telangiectasia
mutated (ATM) gene encodes a serine/threonine protein
kinase that plays a critical role in genomic surveillance and
development. Here, we use a peptide library approach to define the
in vitro substrate specificity of ATM kinase activity. The
peptide library analysis identified an optimal sequence with a central
core motif of LSQE that is preferentially phosphorylated by ATM. The
contributions of the amino acids surrounding serine in the LSQE motif
were assessed by utilizing specific peptide libraries or individual
peptide substrates. All amino acids comprising the LSQE sequence were
critical for maximum peptide substrate suitability for ATM. The
DNA-dependent protein
kinase (DNA-PK), a Ser/Thr kinase related to ATM and
important in DNA repair, was compared with ATM in terms of peptide
substrate selectivity. DNA-PK was found to be unique in its preference
of neighboring amino acids to the phosphorylated serine. Peptide
library analyses defined a preferred amino acid motif for ATM that
permits clear distinctions between ATM and DNA-PK kinase activity. Data
base searches using the library-derived ATM sequence identified
previously characterized substrates of ATM, as well as novel candidate
substrate targets that may function downstream in ATM-directed
signaling pathways.
 |
INTRODUCTION |
Cells respond to DNA damage by activating specific signaling
pathways that culminate into cell cycle checkpoints, in which cell
cycle progression is arrested and DNA repair is effected (1). These
checkpoints are regulated, in part, by members of the phosphoinositide
kinase (PIK)1 family of high
molecular weight proteins, with homologues in yeast,
Drosophila, and mammals (2, 3, 16). The mammalian PIK
representatives include ATM, ataxia
telangiectasia related (ATR), and mammalian
target of rapamycin (mTOR, also known as FRAP) (4). The catalytic
subunit of DNA-PK (DNA-PKcs) is a mammalian PIK family member important
for DNA double strand break repair (5, 6). ATM, ATR, DNA-PKcs, and mTor
have all been shown to express a serine/threonine protein kinase
activity (3-5, 7-9). DNA-PKcs and ATM have been shown to associate
with DNA (6-8). For DNA-PKcs, binding to double strand DNA is
essential for its catalytic activity, whereas ATM kinase activity
appears mildly enhanced for certain protein substrate targets in the
presence of single- and double-stranded DNA. PIK family members in
lower eukaryotes with homology to mammalian counterparts in both
sequence and function include Mei-41 (Drosophila) and yeast
Mec1p, Rad3p, Tel1p, Tor1p, and Tor2p (9). Genetic analyses of yeast
PIK-related genes have in large part established their various roles as
cell cycle checkpoint genes, and defined signaling pathways that are modulated by these gene products (10).
ATM functional loss in humans results in ataxia telangiectasia (A-T)
(11), an autosomal recessive, pleiotrophic disorder characterized by a
progressive cerebellar degeneration, immunodeficiencies, chromosomal
instability, sensitivity to ionizing radiation, sterility, defects in
cell-mediated immunity, and telangiectases of the eyes, and sometimes,
ears, face, and hands (12). A-T patients exhibit a high predisposition
for malignancies, predominantly lymphoid in nature, and A-T-derived
cell lines demonstrate cell cycle checkpoint dysfunction in
G1/S and G2/M in response to DNA-damaging
agents (12, 13). Targeted mutations of ATM in mice recapitulate many aspects of the human phenotype; however, a major difference is that the
mutant mice exhibit a minimal or mild neurogenic phenotype (14-16).
Naturally occurring DNA-PKcs mutations have been characterized in mice
and Arabian foals (17-19); in both species, these mutations result in
a severe combined immunodeficiency syndrome (Scid). The Scid phenotype
results from loss of efficient DNA repair in V(D)J recombination
reactions (20-22). In mice, DNA-PK deficiencies result in a
comparatively milder predisposition for lymphoid malignancies than is
observed in ATM
/
animals. Although Scid-derived cells demonstrate
sensitivity to ionizing radiation, these cells exhibit no obvious cell
cycle checkpoint deficits (23). The functional loss phenotypes suggest
fundamental differences in the downstream substrates/effectors of
DNA-PKcs and ATM.
Studies investigating localization have found ATM in both the nucleus
and cytoplasm, and the extent of ATM in these locations appears
cell-specific. Thus, in proliferating lymphoblastoid cells, ATM is
predominantly in the nucleus and less in the cytoplasm, whereas in
post-mitotic Purkinje cells, ATM resides almost exclusively in the
cytoplasm, suggesting intriguing differences in ATM function and
tissue-specific distinctions in ATM-directed signaling pathways (24-27). Since ATM has been shown to be in several locales, this complicates a unifying characterization of ATM-signaling pathways, except for a general dependence on protein kinase activity likely required in most cases (28). The multiple, wide ranging disorders resulting from ATM loss of function hint at the impact of ATM upon a
multiplicity of biological systems. Some of these disorders, such as
development of lymphoid malignancies and Purkinje cell degeneration (in
human), on the surface appear only remotely connected. However, the
consequences of ATM function, or loss of such even in quite different
tissues, may be ultimately related, at least in part, through
appropriate regulation of decisions pertaining to cell survival or cell death.
Downstream targets of ATM kinase activity that partially delineate DNA
damage-activated cell cycle checkpoint signaling pathways have been
recently described. The best characterized of these checkpoint pathways
involve p53 and Chk2/Cds1, as internally critical components. A DNA
damage-induced ATM-dependent p53 activation pathway has
been shown to involve direct phosphorylation of Ser15 in
p53 by ATM (29-32). ATM phosphorylation and apparent ATM-directed dephosphorylation of certain serines in the C-terminal region of p53
has been shown to modulate multiple aspects of p53 activity including
expression, DNA binding, transcriptional activation, and negative
regulation (29-33). Cds1/Chk2 is modified in response to DNA damage
and is a Ser/Thr kinase that phosphorylates Ser216 of
Cdc25C phosphatase resulting in negative regulation of Cdc2 and cell
cycle arrest (1, 34-36). Phosphorylation and activation of Cds1/Chk2
as a result of ionizing radiation has been shown to be dependent on the
presence of ATM (34-36). Several other target substrates for ATM have
been described, for example, c-Abl, RPA, and BRCA1 (6, 7, 23, 37-39),
but the participating signaling pathways are less clear.
We have employed an oriented degenerate peptide library approach to
determine an optimal substrate motif for ATM protein kinase activity.
This motif was used as a probe to distinguish ATM and DNA-PK catalytic
activities. The peptide library-derived substrate sequence was also
utilized in data base searches that identified both previously defined
substrates as well as potential downstream targets of ATM.
 |
EXPERIMENTAL PROCEDURES |
Cells--
G361, a human melanoma cell line that produces a high
level of ATM protein, and C3ABR and L6, two EBV-transformed human B cell lines, have been described previously (29). All were grown in RPMI
containing 10% heat-inactivated fetal calf serum (Atlanta Biologicals), 200 µM L-Glu and
penicillin/streptomycin.
Peptide Libraries--
The following degenerate peptide
libraries were used as substrates in this study: SF,
MAXXXXSFXXXXAKKK; SI,
MAXXXXXXSIXXXXAKKK; SP,
MAXXXXSPXXXXAKKK; RXXS,
MAXXXXRXXSXXXXAKKK; SQ,
MAXXXXXXXSQXXXXAKKK; S,
MAXXXXSXXXXAKKK; T,
MAXXXXTXXXXAKKK; 4Y4+/
,
MAXXXXYXXXXAKKK (the + and
designations denote the presence or absence of Ser and Thr in the
degenerate positions). The SQ library also contains Ser, Thr, and Tyr
at degenerate positions. The other Ser-based libraries contained all
amino acids but Cys, Trp, Ser, Thr, and Tyr. The Tyr-based libraries
contained all amino acids but Cys, Trp, and Tyr, and the + or
signs designate the presence of Ser and Thr. The SQII library is
comprised of the following: MA
(G,H,R,A)(A,V,F,M,L,Q)(H,A,R)(F,M,Y,A)(Y,F,M,L,V,A)(A,R,P,H,Q,N)(L,Y,N,F,A)SQ(Q,S,R,P,V,E,A)(L,F,P,S,V,Q)(A,Q,F,L)(A,H,N) AKKK. Amino acids at each position are in the parentheses.
ATM Protein Kinase Assays, Peptide Libraries--
ATM Protein
kinase assays were performed as described (31). Cell pellets per 150-cm
plate containing 1.0-2.0 × 107 cells were harvested
when cell growth was approximately 90% confluent for G361 melanoma
cell lines. Cells (7.5 × 106- 1.0 × 107), harvested from 100 ml C3ABR or L6, were washed twice
in ice-cold phosphate-buffered saline, transferred to 1.5-ml Eppendorf
microcentrifuge tubes, and washed a third time using an Eppendorf
microcentrifuge (3000 rpm, 5 min). The supernatant was discarded, and
the cell pellets were either used immediately or stored at
80 °C
prior to use. Previously frozen cells were best for optimal ATM kinase activity, and pellets that had been stored for up to 6 months were
usable in these assays. Cell extracts, ranging between 1.5 and 2.0 mg/ml Bradford (Bio-Rad), were generated as described (31) and used
immediately as storage of extracts usually resulted in a substantial
drop on ATM kinase activity. To the Lysis, High Salt, and Base buffers
(see below and Ref. 31), 1 mM each of NaF and
NaVO3 were added as phosphatase inhibitors. Generally, 20 µl of spent media, containing the monoclonal anti-ATM 10G31 from an
IgG1-producing hybridoma directed against a peptide to positions
819-844 in ATM (29), was added to 1.5-2.0 mg of total lysate and
rocked gently at 4 °C for 3 h. Sheep anti-mouse IgG complexed
to magnetic beads (100 µl/sample) (Dynabeads, Dynal Corp.) was washed
three times with Lysis buffer using a Magnetic Particle Concentrator
(Dynal), reconstituted with 100 µl of Lysis buffer, added to the
antibody/lysate mixture, and subsequently incubated, rocking gently, at
4 °C for 1.5 h.
Following the 1.5-h immunoprecipitation period with the anti-mouse
Ig-containing magnetic beads, the supernatant was discarded, and the
beads were washed three times with Lysis buffer. A High Salt buffer was
added to the metal beads followed by incubation on ice for 5 min to
de-activate DNA-PK (31). The High Salt buffer was removed, and the
beads were washed once with Base buffer (10 mM
MgCl2, 150 mM NaCl, and 100 mM
HEPES, pH 7.5) and once with Kinase buffer containing both 10 mM Mg2+ and 10 mM Mn2+,
100 mM HEPES, pH 7.5, 150 mM NaCl, 100 µM cold ATP, 2 mM dithiothreitol, 50 nM microcystin (Alexis Corp.), 4 µg/ml each of leupeptin,
pepstatin, and 4-(2-aminoethyl)benzenesulfonyl fluoride (Sigma) and 10 µCi of [
-32P]ATP (NEN Life Science Products).
(Initial experiments depicted in Fig. 1A only were carried
out with approximately 100 µCi of [
-32P]ATP.) All
reagents utilized for washes contained NaF and NaVO3 except
for the Kinase buffer that contained microcystin. Samples were prepared
and kept on ice prior to incubation at 30 °C. Reactions were carried
out in a total volume of 30 µl of kinase buffer added to the magnetic
beads. Where indicated, wortmannin was added, usually at 0.5 or 1 µM final concentration, to samples that had been washed
three times in Lysis buffer and once in Base buffer and were brought up
to volume (usually 50 µl) in Base buffer. The samples were allowed to
react with wortmannin by incubation at room temperature for 20 min.
This room temperature preincubation stage resulted in some net loss in
overall ATM activity in the absence of wortmannin. Wortmannin
inhibition persisted for at least 16-18 h without significant loss of
inhibiting activity.2
Phosphorylation assays were measured by removing 2-3.5 µl from kinase reactions at given time points and adding these aliquots to an
equal volume of 30% acetic acid to stop the reaction. Aliquots (3.5-4.0 µl) of the halted reactions were then spotted on p81 phosphocellulose paper, allowed to dry, washed 3 times in 1%
orthophosphoric acid (5-10 min/wash), and counted.
DNA-PK Protein Kinase Assays--
Protein kinase activity of
DNA-PK was assayed using purified DNA-PKcs, and Ku70 and Ku80 were
prepared as described previously (40). Briefly, the kinase reaction was
carried out in the presence of DNA-PKcs (120 ng), Ku80/Ku70 (30 ng),
and a final concentration of 100 µM ATP, 10 µCi of
[
-32P]ATP, 10 mM MgCl2, or
MnCl2, 200 ng of sonicated calf thymus DNA, 50 mM HEPES, pH 7.5, 1 mM dithiothreitol, 0.2 mM EGTA, and 75 mM KCl in a 30-µl reaction
volume. Samples were incubated at 30 °C, and aliquots were
withdrawn, added to an equal volume of 30% glacial acetic acid,
spotted on P81 paper, washed, and analyzed as described for ATM. In the
absence of DNA, DNA-PKcs demonstrated residual activity, and isolated
Ku70/Ku80 exhibited no kinase activity (data not shown). Peptide
Library kinase assays by ATM and DNA-PK were independently evaluated at
least twice, and generally, aspects of the assays were reproduced
several times.
Large Scale Peptide Library Analysis--
Methods for preparing
samples have been described extensively (41). Briefly, 1 mg of peptide
library was exposed to ATM phosphorylation activity in the presence of
0.33 µCi of [
-32P]ATP and 300 µM cold
ATP and calculated to phosphorylate approximately 1% of the peptides
in the library (41). The kinase reaction (300 µl) was terminated by
adding an equal volume of 30% acetic acid and then desalted and
purified over a 1-ml DEAE-Sephacel (Sigma) column to remove excess ATP.
The void volume was usually discarded, and the samples, monitored
through the presence of radioisotope, were lyophilized. Lyophilized
samples were reconstituted in distilled, sterile H2O and
applied to a ferric chelation nitrilotriacetic acid column as described
(41). Eluted samples were pooled and sequenced. Each cycle was
normalized internally to all amino acids included at that position, and
amino acid selectivity at a given cycle was assessed using a program
developed specifically for that
purpose.3 The SQ and SQII
libraries were each analyzed in independent experiments at least twice.
 |
RESULTS |
Preferential Phosphorylation of a Fixed, Degenerate Peptide Library
by ATM--
Immunoprecipitated ATM has been shown to express a Ser/Thr
protein kinase activity that phosphorylates certain protein substrates (6, 29-31). To establish an initial priority for peptide substrate targets, we compared two degenerate peptide libraries as substrates for
immunoprecipitated ATM protein kinase. These libraries contained four
degenerate positions on both the N- and C-terminal sides of a fixed
serine or threonine and were designated the Ser and Thr libraries,
respectively. Our analysis showed that the Ser degenerate library was
phosphorylated more than the Thr library (Fig.
1A).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 1.
Phosphorylation of fixed, degenerate peptide
libraries by ATM Ser/Thr protein kinase activity. A,
analysis of fixed serine (Ser) and threonine (Thr) peptide
libraries. Composition of Ser and Thr libraries is described under
"Experimental Procedures." A representative experiment is presented
in which 100 µg of the Ser or Thr degenerate libraries was added to a
kinase reaction containing immunoprecipitated ATM. Samples were removed
at indicated time points and assayed for phosphorylation by ATM by
counts derived from radioisotope labeling of peptides. B,
comparative ATM phosphorylation of second generation fixed Ser peptide
libraries that also contain an additional fixed amino acid. Samples for
each library (100 µg/kinase reaction) were analyzed as described in
A. The RXXS library is a shorthand notation for a
degenerate library synthesized as MA XXXX
RXXS XXXX A KKK. Other libraries
are described under "Experimental Procedures." C,
specific phosphorylation of the SQ peptide library by ATM. Anti-ATM
immunoprecipitates were prepared from EBV-transformed human B cell
lines C3ABR (C3) and L6, containing wild-type ATM, and ATM with a stop
codon at position 35, respectively (42). Phosphorylation of the SQ
library (100 µg/reaction) by these immunoprecipitates was performed
in the absence (W ) or presence (W+) of 1 µM wortmannin.
|
|
Due to the preferred Ser selection, we proceeded to screen additional
second generation degenerate peptide libraries, several of which
contained a second fixed residue at the +1-position (C-terminal to
Ser). These analyses revealed a strong preference for the SQ library
that exceeded a second tier of selected libraries severalfold (Fig.
1B). Libraries with hydrophobic amino acids at the
+1-position (SI and SF) were somewhat preferred over the Ser library
where the +1-position was degenerate. Arginine at position
3 (the
RXXS library) was selected equivalently to the SI and SF
libraries. Proline at the +1-position resulted in minimal
phosphorylation (Fig. 1B). ATM showed little or no
phosphorylation of a library with a central, fixed tyrosine containing
no Ser or Thr (Fig. 1B). Strikingly, the 4Y4+ library, which
does contain Ser and Thr in the degenerate positions, was selected
equivalently to the SF library, consistent with a preference by ATM for
hydrophobic aromatic residues at the +1-position or elsewhere within
the sequence. We found that utilization of Mn2+
versus Mg2+ in the kinase reaction was essential
for efficient phosphorylation of the SF, SI, and 4Y4+ libraries (data
not shown). The SQ library was more highly phosphorylated in the
presence of Mn2+, although significant phosphorylation
still occurred in Mg2+. On the basis of the results in Fig.
1B, the SQ peptide library was selected for further analyses.
Phosphorylation of the SQ Library Depends on the ATM Protein and
Its Catalytic Activity--
The C3ABR and L6 EBV-transformed human B
cell lines represent cells with wild-type ATM and mutant (null) ATM,
respectively; the latter contains a stop codon at-position 35 in ATM
(42). As expected, the SQ library was highly phosphorylated in ATM
immunoprecipitation assays of protein extracts derived from C3ABR,
whereas immunoprecipitates from L6 demonstrated substantially less
activity (Fig. 1C). Previous studies have shown that ATM is
highly sensitive to wortmannin, a fungal herbicide inhibitor (9, 29,
30, 34). Fig. 1C shows that 1 µM wortmannin
severely diminished phosphorylation of the SQ library. We conclude from
these analyses that the kinase in the immunoprecipitates responsible
for phosphorylation of the SQ library is ATM.
Determination of an Optimal Motif for ATM Protein Kinase
Activity--
Large scale preparative peptide library analyses were
undertaken to isolate the peptides in the SQ library that were
selectively phosphorylated by ATM. The phosphopeptides were eluted from
a ferric chelation column, as described (41), pooled, and sequenced. Table I summarizes the amino acids that
appear in the greatest abundance at positions N-terminal or C-terminal
of the fixed SQ in the subgroup of peptides that are preferentially
phosphorylated by ATM. We observed a relatively strong selection for
peptides with hydrophobic residues at the
1-position (Tyr, Leu, and
Phe) and for Glu or Gln at the +2-position. In order to evaluate
further the observed selectivity in the SQ library, a second library
was constructed (SQII) in which the degenerate positions were biased toward residues selected from the SQ library experiment. As expected, this library was a better substrate for ATM than the SQ library (Fig.
2). The results obtained with the SQII
library were generally consistent with those obtained from the more
degenerate SQ library and provided confirmatory or more reliable
rankings of the values at several positions (Table I).
View this table:
[in this window]
[in a new window]
|
Table I
Amino acid selections at positions N- and C-terminal to the phospho-Ser
in peptides preferentially phosphorylated by ATM
The SQ library used had the composition of
MAXXXXXXXSQXXXXAKKK, where X stands
for all residues except Cys and Trp. Approximately 1% of the library
was phosphorylated by ATM. The phosphopeptides were separated from the
non-phosphorylated peptides and sequenced as a batch by Edman
degradation. Residues exhibiting the strongest preference values are
shown. The amino acid selection values at each position were calculated
as described (64); based on these calculations, 1.00 is defined as the
normalized base-line value; residues with preference values at 1.00 or
below are considered non-selected (see Ref. 64). The SQII library was
biased toward amino acids selected from the SQ library and
significantly less degenerate. Composition of the SQII library is
MA(G,H,R,A)(A,V,F,M,L,Q)(H,A,R)(F,M,Y,A)(Y,F,M,L,V,A)(A,R,P,H,Q,N)(L,Y,N,F,A)
SQ)(Q, S,R,P,V,E,A)(L,F,P,S,V,Q)(A,Q,F,L)(A,H,N)AKKK. Amino acids at
each position are in parentheses.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
Increased phosphorylation of successively
more mature fixed SQ peptide libraries. A representative
experiment in which each library (100 µg) was assayed for
phosphorylation by ATM at the indicated time points is shown.
|
|
Analysis of the SQ II library revealed a strong selection for leucine
and glutamate at the
1- and +2-positions, respectively, relative to
the phosphorylated Ser. N-terminal to Ser, there was a strong selection
for Ala at the
5-position and Gly at
7. Gln was highly selected at
several positions, including
2 and
4 as well as +2 and +3. Valine
was also selected at the +2-position. Most of the other positions had
weak selections. We found selectivity for proline at the
2- and
+4-positions relative to Ser (note SQII library selection). On the
basis of the library selections, we were able to derive a predicted
optimal substrate motif, depicted in Table I. Interestingly, the
predicted optimal substrate closely resembles the sequence at the major
ATM phosphorylation site in p53. In particular, both the optimal
substrate sequence and p53 share a core motif of LSQE. (Table I). The
library-derived optimal motif served as the reference for synthesis of
individual peptides utilized for further analyses (see below).
Evaluation of Predicted Optimal Peptide Substrates of ATM--
We
compared the optimal peptide generated from the library analysis,
designated ATide, versus a peptide derived from the
N-terminal sequence of p53 (p53-WT) (see Table
II). These two peptides both contained
the core LSQE sequence and demonstrated nearly identical Km and Vmax values (Table
III). To determine the importance of the
Leu at
1 and Glu at +2 for substrate utilization, these residues were
changed to Ala in the context of the ATide and p53 sequences. In both
cases, conversion of the Leu
1 to Ala caused a 1.7- and
2.4-fold decrease, respectively, in the
Vmax/Km values due to an
increase in the Km. Conversion of Glu+2
to Ala (Table II) had a more severe effect, resulting in an approximate 10-fold increased Km of the ATide sequence and a
4-fold increase in the Km of the p53 sequence (Table
III). These results are consistent with the peptide library experiment
where Glu at +2 exhibited a higher selectivity score than Leu at
1 (Table I).
View this table:
[in this window]
[in a new window]
|
Table II
Sequences of the ATide and p53 peptides
ATide peptides are derived from the optimal sequence derived from
peptide library analyses (see Table I) and used for the analyses shown
in Tables II and III. The p53-WT peptide contains the sequences
surrounding Ser15 position in p53. For purposes of simplicity,
the Ser residues at positions 9 and 20 and Thr at position 18 in the
native sequence was changed to Ala (5).
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Vmax and Km values of ATide and p53 peptides
ATide and p53 peptides were assayed at several concentrations ranging
from 10 µM to 2 mM in immunoprecipitated ATM
kinase assays to derive Km and
Vmax values.
|
|
Comparison of DNA-PK to ATM with Regard to Peptide Substrate
Preference--
The DNA-PK heterotrimeric complex has been shown to
actively phosphorylate a multitude of target substrates; however, it
remains unclear which, if any, of these targets have true physiological relevance. A central SQ motif has been previously determined to be an
important sequence for DNA-PK phosphorylation (5, 43). We screened
several degenerate peptide libraries for selection in terms of DNA-PK
kinase activity. We found that the library preferences by DNA-PK were
similar to that of ATM in that the SQ library was by far the most
highly phosphorylated of the degenerate peptide libraries (Fig.
3 and data not shown). DNA-PK also
phosphorylated the SI, SF, and 4Y4+ libraries better in
Mn2+ than in Mg2+ with the interesting
exception of the SQ library, the latter of which was more highly
phosphorylated in the presence of Mg2+ (Fig. 3 and data not
shown). Phosphorylation of the 4Y4+ library was presumably on Ser/Thr
residues since the same library lacking these residues (4Y4
) was not
phosphorylated (Fig. 3). The modest preference of DNA-PK for the SP
library was equivalent in the presence of either cation.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 3.
Preferential selection of the SQ peptide
library by DNA-PK. Degenerate peptide libraries (100 µg) were
assayed in the presence of Mn2+, in a reaction mix
containing DNA-PKcs, Ku70, Ku80, and 200 ng calf thymus (see under
"Experimental Procedures"), and assayed at indicated time points
for levels of phosphorylation.
|
|
Although these results indicate similarities between DNA-PK and ATM in
peptide substrate preferences, there were several significant differences. ATM phosphorylated the SQII library about 30% better than
the SQ library (see Fig. 2). By contrast, there was an approximately 350% increase in the phosphorylation of the SQ library
versus the significantly less degenerate SQII library by
DNA-PK (Fig. 3). The difference between the two kinases was also
reflected in their relative preferences for the various ATide and p53
peptides. Although these peptides were readily phosphorylated by
DNA-PK, the Km values in general were apparently
much higher than observed with ATM and could not be readily determined;
we were unable to reach a Vmax value
(i.e. saturate DNA-PK catalytic activity) with the peptides
used in this study. Table IV presents the
relative ratio of peptide phosphorylation by DNA-PK at a single peptide
concentration (100 µM). Of interest, the Leu
1
Ala substitution in the context of either the ATide or p53
peptides resulted in an increase rather than decrease in
phosphorylation rate, indicating that DNA-PK differs from ATM in amino
acid selections at the
1-position. In contrast to ATM, there was a
clear preference for the ATide peptide versus the p53-WT
peptide by DNA-PK (Tables III and IV). Similar to ATM, the +2-position
also plays a critical role in substrate preference in that the
Glu+2
Ala substitution severely diminished DNA-PK
phosphorylation in both the ATide and p53 peptides. Calculated
Vmax/Km values for DNA-PK
were in complete agreement with the normalized data presented in Table
IV (see also Table III).
View this table:
[in this window]
[in a new window]
|
Table IV
Peptide substrate specificity of DNA-PK
These rates were derived from assays of phosphorylation kinetics for
each of the peptide substrates. Several peptide concentrations were
analyzed for each of the six peptides tested with similar results to
the values obtained for 100 µM (data not shown).
|
|
Silver stain analyses show an approximate level of 200-250 ng of
immunoprecipitated ATM in G361 cells in a typical kinase reaction (data
not shown). Utilization of an estimated value of 250 ng per reaction
for ATM allowed us to compare the relative velocities of ATM and DNA-PK
(the latter previously determined at 120 ng per
reaction.4 Phosphorylation of
Atide peptide (100 µM) by the two PIK kinase was assayed
after 10 min at 30 °C. Under these conditions, our analysis revealed
that ATM catalytic activity was about 78 pmol/min/µg and DNA-PK was
410 pmol/min/µg. Thus, under our specific assay conditions, DNA-PK
appeared to demonstrate approximately 10-fold higher activity than ATM
as measured by ATP turnover.
 |
DISCUSSION |
A major advantage of the peptide library approach is that it
permits an essentially unbiased query of an enormous library of
individual peptides (in the case of the SQ library, approximately 1.8 × 1012 peptides) for derivation of an optimal
substrate motif for ATM kinase activity. Within the sequence of this
optimal substrate, we have identified a central core motif comprised of
LSQE shared by both the derived ATM peptide substrate and amino acids
14-17 in p53, an endogenous downstream substrate. Our results indicate that the
1-, +1-, and +2-positions relative to Ser are all important for ATM and DNA-PK catalytic activities. However, these positions are
weighted in a comparative sense, with the C-terminal +1- and +2-positions playing significantly more critical roles in defining substrate preference. Additionally, several positions N-terminal to Ser
(e.g. Gln/Pro at
2 and Ala at
5) and the C-terminal
+3-position (Gln/Val) also demonstrated relatively high preference
values in the library analyses. Comparative analyses of ATM and DNA-PK peptide preferences permitted clear distinctions to be drawn between the substrate requirements of the two PIK family kinases.
Differences in ATM and DNA-PK catalytic activity were readily apparent
by several criteria. The less degenerate SQII library was much more
highly selected by ATM than the SQ library in contrast to the reverse
for DNA-PK, in which the SQII library is only moderately selected over
the second group of libraries (i.e. the 4Y4+, SF, and SI
libraries) phosphorylated by the latter. Significantly, these data
further support the critical role of amino acids surrounding the SQ
motif in dictating or defining substrate preferences for ATM and
DNA-PK. Of interest, we were unable to saturate DNA-PK catalytic
activity with the peptides used in this study. By contrast, Vmax values were readily obtained for ATM. ATM
exhibited little or no selectivity for the SP degenerate library in
contrast to the modest preference demonstrated by DNA-PK. Conversely,
the RXXS library was mildly selected by ATM but not
DNA-PK.
A significant point of departure of the two PIK kinases is reflected in
the strong preference by DNA-PK for the ATide sequence versus the p53-WT peptide. This preference is in contrast to
the equivalent phosphorylation of the two peptides by ATM. Distinct from ATM, the Leu
1
Ala interchange is preferred by
DNA-PK. Indeed, we have assayed DNA-PK substrate preferences using the
SQ library and find notable differences in residue preferences of
DNA-PK at the
1-position and
elsewhere.5 Similar to the
situation with ATM, the Glu2
Ala substitution severely
compromised both the AT and p53 peptides as substrates for DNA-PK.
Thus, in the context of the peptide libraries and individual peptides
assayed in this study, DNA-PK demonstrated a unique substrate
preference pattern when compared with ATM. By inference, ATM and DNA-PK
should preferentially phosphorylate fundamentally different downstream
substrates. The null phenotypes of ATM and DNA-PK exhibit profound
differences (14-16, 44-46) also arguing for a significant divergence
of ATM and DNA-PK downstream signaling pathways.
We find that similar to DNA-PK (which is assayed in the context of
highly purified DNA-PKcs, Ku80/Ku70, and DNA), immunoprecipitated ATM
is also a robust Ser/Thr protein kinase, although less active than
DNA-PK. This variance may reflect inherent differences in the two
kinases or indicate that ATM is being assayed under less ideal
conditions. Nevertheless, the substantial level of protein kinase
activity manifested by ATM in vitro has potentially
important implications regarding its in vivo functions, both
as a component in cell cycle checkpoint control as well as its role in
development. The activities of both ATM and DNA-PK likely require
stringent control processes or physically associated factors that
modulate accessibility of the kinase activity of the two PIK family
members if, in fact, the observed high level kinase activities extend to in vivo function. For DNA-PK, there is an essential
requirement for the presence of DNA for catalytic activity.
Additionally, autophosphorylation of the DNA-PKcs subunit of the
complex has been correlated with down-regulation of protein kinase
activity (63). Regulation of ATM kinase activity remains unknown.
DNA-PK has been previously shown to prefer SQ sequences (5, 43). We
have also found an extremely high selectivity by DNA-PK protein kinase
activity for the SQ degenerate library over several other libraries
with different fixed +1 amino acids. Overall, the library and
individual peptide selectivity pattern of DNA-PK indicates a strong
possibility for substrate target overlap between ATM and DNA-PK. In
this regard, ATR is a third mammalian PIK kinase with apparent
specificity for Ser15 in p53 and may also participate
through shared substrate preferences of ATM and DNA-PK (3, 4). PIK
kinase localization and developmental expression patterns, together
with accessibility of a given substrate within the microenvironment or
complex containing active PIK kinases, would likely play key roles in
dictating phosphorylation of a substrate and subsequent physiological consequences.
Our results show that substrate requirements for DNA-PK and ATM are
modestly flexible with respect to the +1-position in that there are two
tiers of substrate preference. In addition to the more highly selected
SQ library, we observed a preference for libraries with hydrophobic
residues at +1. These lesser preferences may well reflect a relevant
class of substrate targets for both ATM and DNA-PK. Examples of
alternative substrate motifs other than SQ have been described for
DNA-PK (see Ref. 5). Additionally, DNA-PK has been shown to
preferentially phosphorylate a Ser6-Tyr site in Ku70 (47).
This site selection, however, is supported by results obtained in the
peptide library analyses. We have likewise observed selectivity for an
aromatic hydrophobic residue at the +1-position as shown by the modest
SF peptide library preference by DNA-PK and inferred by 4Y4+ library
selectivity, i.e. indicating a possible selection for Tyr
nearby the targeted Ser/Thr. Phosphoamino acid analysis of the
DNA-PK-phosphorylated 4y4+ library showed mainly phosphoserine and
little or no evidence for
phosphotyrosine.6
Additionally, the 4Y4- library, which contains only the fixed Tyr and
no Ser, Thr, or Tyr residues in the degenerate
positions, was not phosphorylated by DNA-PK. The 4Y4+ and SF
preferences by DNA-PK are also observed for ATM.
A recent study reported derivation of a consensus substrate sequence of
(P,L,I,M)X(L,I,D,E) SQ for ATM using a glutathione S-transferase (GST) peptide fusion approach that adopted the
wild-type p53 sequence as a template (48). In this analysis, a short
sequence consisting of the N-terminal amino acids surrounding
Ser15 in p53 was fused to GST, and various amino acid
substitutions within the GST-fused peptides were tested in ATM kinase
gel-based assays for overall substrate suitability. Similarities in
results obtained in this approach with the present study include a
preference for Ser versus Thr, selection for Gln at the
+1-position, and a preference for hydrophobic residues at the
1- and
3-positions. The RXXS library, containing a basic residue
at the
3-position, was modestly selected among the degenerate
libraries and may be important as a relevant "second tier" target
motif. However, in more extensive analyses (see Table I), we found
little or no preference by ATM for basic residues. Positively charged
amino acids appeared to adversely affect phosphorylation of the GST peptides (48). The results of the peptide library analysis
significantly extends the consensus substrate motif of ATM both
N-terminal, and in particular, C-terminal to the so-called "SQ
motif." Searches through the genomic data base using consensus
sequences derived from the two separate approaches yielded several
similar possible substrate targets.
Data base searches using sequences obtained from the peptide library
analysis of ATM substrate preference (see Table I) revealed a number of
intriguing potential downstream target molecules that might conceivably
play a role in ATM-signaling pathways. Table V is a partial listing of a group of
candidate molecules that contain sites that most resemble the sequences
derived from the SQ and SQII library preference values (Table I). Sites
of ATM phosphorylation have been identified in p53 and Brca-1, and some of these were also identified in data base searches using the derived
sequence from library analysis thus providing additional validation for
the library-derived sequence. Several of the Brca-1 serines apparently
phosphorylated by ATM were at SQ sites (39). The tumor suppressor p53
has been previously shown to be a relevant in vivo target
for ATM, and our study strongly supports p53 as an important downstream
target of ATM. Conversely, the comparatively weaker p53 peptide
selectivity by DNA-PK kinase activity indicates a less compelling role
for p53 in signaling pathways that utilize DNA-PK (49). Although we are
able to observe robust ATM and DNA-PK phosphorylation of several
in vitro targets (e.g. Mdm2, Cds1, Chk1, Nbs1,
and XRCC4; data not shown), the true value of any predicted substrate
is determined through in vivo analyses, and these
experiments are clearly the next step in this study.
View this table:
[in this window]
[in a new window]
|
Table V
ATM phosphorylation sites
Candidate substrate targets for ATM listed are within 0.01 percentile match-selected using a data base search engine developed in
the Cantley lab.7 H and M indicate human and mouse homologues,
respectively. The position of the serine or threonine within the
protein selected as a presumed substrate target is superscript. Data
base searches utilized a preference matrix produced and weighted
relative to the peptide library preference values shown in Table I for
the SQ and SQII libraries. The resulting percentile matches range from
the highest (0.001% for p53) to the lowest (1.7% for Ser at position
357 in Cds1) percentiles, for the best suited and less preferred
motifs, respectively, within putative targets selected in data base
searches. H indicates human, M indicates mouse. See text for
discussion.
|
|
We find potential sites on several substrates previously identified as
targets for ATM phosphorylation, including PHAS-1 (which contains
multiple sites), Abl, and Cds1/Chk2. PHAS-1 has been used as an
indicator substrate for ATM phosphorylation activity; no relevance has
been established for this substrate in vivo. Cds1/Chk2 has
been identified as a downstream component of ATM, and Cds1/Chk2
contains several promising sites, the best of which are shown in Table
V. Conservation of certain aspects of mammalian checkpoint signaling
pathways involving ATM and Cds1/Chk2 with those of yeast utilizing PIK
homologues to ATM is also apparent if similar motifs are targeted as
substrates in yeast. For example, Rad3 (an ATM homologue in
Schizosaccharomyces pombe) is upstream of yeast Cds1 (see,
for example, Ref. 50). Recent evidence suggests that in
Saccharomyces cerevisiae, the MEC1 PIK family member and RAD9 cooperate to activate independent Rad53 and Chk1-signaling pathways that collectively form a DNA damage-activated cell cycle checkpoint (51).
ATM is cytoplasmic in several types of neuronal cells including
Purkinje cells (24-27, 52). A yeast two-hybrid screen revealed a
-adaptin association with ATM, and a
-neuronal adaptin-like protein (
-NAP)·ATM complex could be demonstrated in
vitro (26).
-NAP and dynactin (see Table V) may play important
roles in vesicle transport in neurons. ATM has been localized to
peroxisomes in primary fibroblast and established cell lines, and
catalase activity has been shown to be decreased in A-T cell lines
(53).
-NAP and catalase contain potential substrate motifs (at
Ser511 and Ser254, respectively), for ATM
kinase activity; however, these sites fall within the lower match
percentiles that are 0.233% for catalase and
-NAP at 0.650%.
-Adaptin contains motifs that are predicted as substantially less
suited. Nevertheless, substrate accessibility and localization may
allow a less ideal sequence (as defined by the present search criteria)
to be offered as a relevant ATM substrate. Together with the several
studies mentioned above, data base searches also predict substrates
that might play tissue-specific roles in terms of ATM-mediated
regulation of essential cytoplasmic metabolism as well as vesicle
transport and function.
Other possible substrate targets of ATM include proteins with roles in
DNA repair and cell cycle checkpoint functions, including Mdm2 and
Nbs-1 (Table V). Mdm2 functions as a negative regulator of p53 (54),
and Ser17(Gln) in Mdm2 has been identified as a site for
in vitro DNA-PK phosphorylation that blocked Mdm2
association with p53 (55). There are several potential sites in Mdm2
that might serve as substrate targets for ATM; the best of these,
located in the C-terminal region of the molecule, are presented in
Table V. Phosphorylation of Mdm2 by ATM may represent an additional
level of cell cycle checkpoint control (56). Nbs-1 (Nibrin) has been
identified as the gene mutated in Nijmegen breakage syndrome, a defect
with repercussions similar in many ways to ATM functional loss
(57-59). Nbs-1 contains several potential substrate motifs for ATM
kinase activity. The Leu-Ser397-Glu-Asp sequence (see Table
V) is intriguing in that phosphorylation of Ser397 occurs
in response to ionizing radiation, and this site is phosphorylated in vitro by ATM (65). Mammalian Wee1 CDK tyrosine kinase has been identified as a positive upstream activator of cyclin dependent kinase Cdc2 activity; hyperphosphorylation may target Wee1 for degradation during certain stages of the cell cycle (60-62). Both ATM
and DNA-PK contain potential motifs that might serve as regulatory auto- or trans-phosphorylation sites (63). These and several other
molecules identified as containing reasonable substrate motifs for ATM
or DNA-PK in Table V may be useful in suggesting additional signaling
pathways modulated by the kinase activities of the two PIK family kinases.
 |
ACKNOWLEDGEMENTS |
We are grateful to Drs. Fred Rosen and Fred
Alt for support and encouragement. Dr. Martin Lavin kindly provided the
C3ABR cell line. We thank Dr. David Weaver for critical comments on the
manuscript. We appreciate the secretarial assistance of Talise Dow.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
b
Both authors contributed equally to this work.
c
Supported by a grant from the Center for Blood Research.
d
Supported by National Institutes of Health Grant GM57018.
j
Supported by National Institutes of Health Grant GM56203.
k
To whom correspondence should be addressed:
Center for Blood Research, Dept. of Pediatrics, Children's Hospital,
Harvard Medical School, 200 Longwood Ave., Boston, MA 02115.
Published, JBC Papers in Press, May 2, 2000, DOI 10.1074/jbc.M001002200
2
G. Rathbun, unpublished observations.
3
J. H. Lai and L. C. Cantley,
unpublished observations.
4
D. Chan and S. Lees-Miller, personal communication.
5
A. Dwyer, D. Chan, T. O'Neill, S. Lees-Miller,
and G. Rathbun, unpublished data.
6
C. Crovello, G. Rathbun, and L. C. Cantley,
unpublished data.
7
H. Leparc and L. C. Cantley, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
PIK, phosphoinositide kinase;
ATM, ataxia
telangiectasia mutated;
ATR, ataxia
telangiectasia-related;
DNA-PKcs, catalytic
subunit of DNA-Dependent Protein
Kinase;
EBV, Epstein-Barr virus;
WT, wild type;
A-T, ataxia
telangiectasia;
Scid, severe combined immunodeficiency syndrome;
-NAP, neuronal adaptin-like protein-
;
GST, glutathione
S-transferase.
 |
REFERENCES |
| 1.
|
Matsuoka, S.,
Huang, M.,
and Elledge, S. J.
(1998)
Science
282,
1893-1897
|
| 2.
|
Hoekstra, M. F.
(1997)
Curr. Opin. Genet. & Dev.
7,
170-175
|
| 3.
|
Lakin, N. D.,
Hann, B. C.,
and Jackson, S. P.
(1999)
Oncogene
18,
3989-3995
|
| 4.
|
Tibbetts, R. S.,
Brumbaugh, K. M.,
Williams, J. M.,
Sarkaria, J. N.,
Cliby, W. A.,
Shieh, S. Y.,
Taya, Y.,
Prives, C.,
and Abraham, R. T.
(1999)
Genes Dev.
13,
152-157
|
| 5.
|
Anderson, C. W.
(1993)
Trends Biochem. Sci.
18,
433-437
|
| 6.
|
Gately, D. P.,
Hittle, J. C.,
Chan, G. K.,
and Yen, T. J.
(1998)
Mol. Biol. Cell
9,
2361-2374
|
| 7.
|
Suzuki, K.,
Kodama, S.,
and Watanabe, M.
(1999)
J. Biol. Chem.
274,
25571-25575
|
| 8.
|
Smith, G. C.,
Cary, R. B.,
Lakin, N. D.,
Hann, B. C.,
Teo, S. H.,
Chen, D. J.,
and Jackson, S. P.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
11134-11139
|
| 9.
|
Abraham, R. T.
(1996)
Curr. Opin. Immunol.
8,
412-418
|
| 10.
|
Carr, A. M.,
and Hoekstra, M. F.
(1995)
Trends Cell Biol
5,
32-40
|
| 11.
|
Savitsky, K.,
Barshira, A.,
Gilad, S.,
Rotman, G.,
Ziv, Y.,
Vanagaite, L.,
Tagle, D. A.,
Smith, S.,
Uziel, T.,
Sfez, S.,
Ashkenazi, M.,
Pecker, I.,
Frydman, M.,
Harnik, R.,
Patanjali, S. R.,
Simmons, A.,
Clines, G. A.,
Sartiel, A.,
Gatti, R. A.,
Chessa, L.,
Sanal, O.,
Lavin, M. F.,
Jaspers, N. G. J.,
Malcolm, A.,
Taylor, R.,
and Shiloh, Y.
(1995)
Science
268,
1749-1753
|
| 12.
|
Sedgwick, R. P.,
and Boder, E.
(1991)
Handb. Clin. Neurol.
16,
347-423
|
| 13.
|
Lavin, M. F.,
and Shiloh, Y.
(1997)
Annu. Rev. Immunol.
15,
177-202
|
| 14.
|
Barlow, C.,
Hirotsune, S.,
Paylor, R.,
Liyanage, M.,
Eckhaus, M.,
Collins, F.,
Shiloh, Y.,
Crawley, J. N.,
Ried, T.,
Tagle, D.,
and Wynshawboris, A.
(1996)
Cell
86,
159-171
|
| 15.
|
Xu, Y.,
Ashley, T.,
Brainerd, E. E.,
Bronson, R. T.,
Meyn, M. S.,
and Baltimore, D.
(1996)
Genes Dev.
10,
2411-2422
|
| 16.
|
Elson, A.,
Wang, Y.,
Daugherty, C. J.,
Morton, C. C.,
Zhou, F.,
Campos-Torres, J.,
and Leder, P.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
13084-13089
|
| 17.
|
Blunt, T.,
Finnie, N. J.,
Taccioli, G. E.,
Smith, G. C. M.,
Demengeot, J.,
Gottlieb, T. M.,
Mizuta, R.,
Varghese, A. J.,
Alt, F. W.,
Jeggo, P. A.,
and Jackson, S. P.
(1995)
Cell
80,
813-823
|
| 18.
|
Hartley, K. O.,
Gell, D.,
Smith, G. C. M.,
Zhang, H.,
Divecha, N.,
Connelly, M. A.,
Admon, A.,
Leesmiller, S. P.,
Anderson, C. W.,
and Jackson, S. P.
(1995)
Cell
82,
849-856
|
| 19.
|
Wiler, R.,
Leber, R.,
Moore, B. B.,
VanDyk, L. F.,
Perryman, L. E.,
and Meek, K.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11485-11489
|
| 20.
|
Schuler, W.,
Weiler, I. J.,
Schuler, A.,
Phillips, R. A.,
Rosenberg, N.,
Mak, T. W.,
Kearney, J. F.,
Perry, R. P.,
and Bosma, M. J.
(1986)
Cell
46,
963-972
|
| 21.
|
Malynn, B. A.,
Blackwell, T. K.,
Fulop, G. M.,
Rathbun, G. A.,
Furley, A. J.,
Ferrier, P.,
Heinke, L. B.,
Phillips, R. A.,
Yancopoulos, G. D.,
and Alt, F. W.
(1988)
Cell
54,
453-460
|
| 22.
|
Lieber, M. R.,
Hesse, J. E.,
Lewis, S.,
Bosma, G. C.,
Rosenberg, N.,
Mizuuchi, K.,
Bosma, M. J.,
and Gellert, M.
(1988)
Cell
55,
7-16
|
| 23.
|
Smith, G. C.,
and Jackson, S. P.
(1999)
Genes Dev.
13,
916-934
|
| 24.
|
Watters, D.,
Khanna, K. K.,
Beamish, H.,
Birrell, G.,
Spring, K.,
Kedar, P.,
Gatei, M.,
Stenzel, D.,
Hobson, K.,
Kozlov, S.,
Zhang, N.,
Farrell, A.,
Ramsay, J.,
Gatti, R.,
and Lavin, M.
(1997)
Oncogene
14,
1911-1921
|
| 25.
|
Oka, A.,
and Takashima, S.
(1998)
Neurosci. Lett.
252,
195-198
|
| 26.
|
Lim, D. S.,
Kirsch, D. G.,
Canman, C. E.,
Ahn, J. H.,
Ziv, Y.,
Newman, L. S.,
Darnell, R. B.,
Shiloh, Y.,
and Kastan, M. B.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
10146-10151
|
| 27.
|
Kuljis, R. O.,
Chen, G.,
Lee, E. Y.,
Aguila, M. C.,
and Xu, Y.
(1999)
Brain Res.
842,
351-358
|
| 28.
|
Chapman, C. R.,
Evans, S. T.,
Carr, A. M.,
and Enoch, T.
(1999)
Mol. Biol. Cell
10,
3223-3238
|
| 29.
|
Banin, S.,
Moyal, L.,
Shieh, S.,
Taya, Y.,
Anderson, C. W.,
Chessa, L.,
Smorodinsky, N. I.,
Prives, C.,
Reiss, Y.,
Shiloh, Y.,
and Ziv, Y.
(1998)
Science
281,
1674-1677
|
| 30.
|
Canman, C. E.,
Lim, D. S.,
Cimprich, K. A.,
Taya, Y.,
Tamai, K.,
Sakaguchi, K.,
Appella, E.,
Kastan, M. B.,
and Siliciano, J. D.
(1998)
Science
281,
1677-1679
|
| 31.
|
Sarkaria, J. N.,
Tibbetts, R. S.,
Busby, E. C.,
Kennedy, A. P.,
Hill, D. E.,
and Abraham, R. T.
(1998)
Cancer Res.
58,
4375-4382
|
| 32.
|
Waterman, M. J.,
Stavridi, E. S.,
Waterman, J. L.,
and Halazonetis, T. D.
(1998)
Nat. Genet.
19,
175-178
|
| 33.
|
Khanna, K. K.,
Keating, K. E.,
Kozlov, S.,
Scott, S.,
Gatei, M.,
Hobson, K.,
Taya, Y.,
Gabrielli, B.,
Chan, D.,
Lees-Miller, S. P.,
and Lavin, M. F.
(1998)
Nat. Genet.
20,
398-400
|
| 34.
|
Sanchez, Y.,
Wong, C.,
Thoma, R. S.,
Richman, R.,
Wu, Z.,
Piwnica-Worms, H.,
and Elledge, S. J.
(1997)
Science
277,
1497-1501
|
| 35.
|
Chaturvedi, P.,
Eng, W. K.,
Zhu, Y.,
Mattern, M. R.,
Mishra, R.,
Hurle, M. R.,
Zhang, X.,
Annan, R. S.,
Lu, Q.,
Faucette, L. F.,
Scott, G. F.,
Li, X.,
Carr, S. A.,
Johnson, R. K.,
Winkler, J. D.,
and Zhou, B. B.
(1999)
Oncogene
18,
4047-4054
|
| 36.
|
Brown, A. L.,
Lee, C. H.,
Schwarz, J. K.,
Mitiku, N.,
Piwnica-Worms, H.,
and Chung, J. H.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3745-3750
|
| 37.
|
Shafman, T.,
Khanna, K. K.,
Kedar, P.,
Spring, K.,
Kozlov, S.,
Yen, T.,
Hobson, K.,
Gatei, M.,
Zhang, N.,
Watters, D.,
Egerton, M.,
Shiloh, Y.,
Kharbanda, S.,
Kufe, D.,
and Lavin, M. F.
(1997)
Nature
387,
520-523
|
| 38.
|
Baskaran, R.,
Wood, L. D.,
Whitaker, L. L.,
Canman, C. E.,
Morgan, S. E.,
Xu, Y.,
Barlow, C.,
Baltimore, D.,
Wynshaw-Boris, A.,
Kastan, M. B.,
and Wang, J. Y.
(1997)
Nature
387,
516-519
|
| 39.
|
Cortez, D.,
Wang, Y.,
Qin, J.,
and Elledge, S. J.
(1999)
Science
286,
1162-1166
|
| 40.
|
Chan, D. W.,
Mody, C. H.,
Ting, N. S.,
and Lees-Miller, S. P.
(1996)
Biochem. Cell Biol.
74,
67-73
|
| 41.
|
Songyang, Z.,
and Cantley, L. C.
(1998)
Methods Mol. Biol.
87,
87-98
|
| 42.
|
Gilad, S.,
Bar-Shira, A.,
Harnik, R.,
Shkedy, D.,
Ziv, Y.,
Khosravi, R.,
Brown, K.,
Vanagaite, L.,
Xu, G.,
Frydman, M.,
Lavin, M. F.,
Hill, D.,
Tagle, D. A.,
and Shiloh, Y.
(1996)
Hum. Mol. Genet.
5,
2033-2037
|
| 43.
|
Lees-Miller, S. P.,
Sakaguchi, K.,
Ullrich, S. J.,
Appella, E.,
and Anderson, C. W.
(1992)
Mol. Cell. Biol.
12,
5041-5049
|
| 44.
|
Gao, Y.,
Chaudhuri, J.,
Zhu, C.,
Davidson, L.,
Weaver, D. T.,
and Alt, F. W.
(1998)
Immunity
9,
367-376
|
| 45.
|
Jhappan, C.,
Morse, H. C., III,
Fleischmann, R. D.,
Gottesman, M. M.,
and Merlino, G.
(1997)
Nat. Genet.
17,
483-486
|
| 46.
|
Taccioli, G. E.,
Amatucci, A. G.,
Beamish, H. J.,
Gell, D.,
Xiang, X. H.,
Torres Arzayus, M. I.,
Priestley, A.,
Jackson, S. P.,
Marshak Rothstein, A.,
Jeggo, P. A.,
and Herrera, V. L.
(1998)
Immunity
9,
355-366
|
| 47.
|
Chan, D. W.,
Ye, R.,
Veillette, C. J.,
and Lees-Miller, S. P.
(1999)
Biochemistry
38,
1819-1828
|
| 48.
|
Kim, S.-T.,
Lim, D. S.,
Canman, C. E.,
and Kastan, M. B.
(1999)
J. Biol. Chem.
274,
37538-37543
|
| 49.
|
Jimenez, G. S.,
Bryntesson, F.,
Torres-Arzayus, M. I.,
Priestley, A.,
Beeche, M.,
Saito, S.,
Sakaguchi, K.,
Appella, E.,
Jeggo, P. A.,
Taccioli, G. E.,
Wahl, G. M.,
and Hubank, M.
(1999)
Nature
400,
81-83
|
| 50.
|
Martinho, R. G.,
Lindsay, H. D.,
Flaggs, G.,
DeMaggio, A. J.,
Hoekstra, M. F.,
Carr, A. M.,
and Bentley, N. J.
(1998)
EMBO J.
17,
7239-7249
|
| 51.
|
Sanchez, Y.,
Bachant, J.,
Wang, H.,
Hu, F.,
Liu, D.,
Tetzlaff, M.,
and Elledge, S. J.
(1999)
Science
286,
1166-1171
|
| 52.
|
Barlow, C.,
Ribaut-Barassin, C.,
Zwingman, T. A.,
Pope, A. J.,
Brown, K. D.,
Owens, J. W.,
Larson, D.,
Harrington, E. A.,
Haeberle, A. M.,
Mariani, J.,
Eckhaus, M.,
Herrup, K.,
Bailly, Y.,
and Wynshaw-Boris, A.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
871-876
|
| 53.
|
Watters, D.,
Kedar, P.,
Spring, K.,
Bjorkman, J.,
Chen, P.,
Gatei, M.,
Birrell, G.,
Garrone, B.,
Srinivasa, P.,
Crane, D. I.,
and Lavin, M. F.
(1999)
J. Biol. Chem.
274,
34277-34282
|
| 54.
|
Kubbutat, M. H.,
Ludwig, R. L.,
Levine, A. J.,
and Vousden, K. H.
(1999)
Cell Growth Differ.
10,
87-92
|
| 55.
|
Mayo, L. D.,
Turchi, J. J.,
and Berberich, S. J.
(1997)
Cancer Res.
57,
5013-5016
|
| 56.
|
Khosravi, R.,
Maya, R.,
Gottlieb, T.,
Oren, M.,
Shiloh, Y.,
and Shkedy, D.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
14973-14977
|
| 57.
|
Carney, J. P.,
Maser, R. S.,
Olivares, H.,
Davis, E. M.,
Le Beau, M.,
Yates, J. R., 3rd,
Hays, L.,
Morgan, W. F.,
and Petrini, J. H.
(1998)
Cell
93,
477-486
|
| 58.
|
Varon, R.,
Vissinga, C.,
Platzer, M.,
Cerosaletti, K. M.,
Chrzanowska, K. H.,
Saar, K.,
Beckmann, G.,
Seemanova, E.,
Cooper, P. R.,
Nowak, N. J.,
Stumm, M.,
Weemaes, C. M.,
Gatti, R. A.,
Wilson, R. K.,
Digweed, M.,
Rosenthal, A.,
Sperling, K.,
Concannon, P.,
and Reis, A.
(1998)
Cell
93,
467-476
|
| 59.
|
Matsuura, S.,
Tauchi, H.,
Nakamura, A.,
Kondo, N.,
Sakamoto, S.,
Endo, S.,
Smeets, D.,
Solder, B.,
Belohradsky, B. H.,
Der Kaloustian, V. M.,
Oshimura, M.,
Isomura, M.,
Nakamura, Y.,
and Komatsu, K.
(1998)
Nat. Genet.
19,
179-181
|
| 60.
|
Igarashi, M.,
Nagata, A.,
Jinno, S.,
Suto, K.,
and Okayama, H.
(1991)
Nature
353,
80-83
|
| 61.
|
McGowan, C. H.,
and Russell, P.
(1995)
EMBO J.
14,
2166-2175
|
| 62.
|
Watanabe, N.,
Broome, M.,
and Hunter, T.
(1995)
EMBO J.
14,
1878-1891
|
| 63.
|
Chan, D. W.,
and Lees-Miller, S. P.
(1996)
J. Biol. Chem.
271,
8936-8941
|
| 64.
|
Songyang, Z.,
Blechner, S.,
Hoagland, N.,
Hoekstra, M. F.,
Piwnica-Worms, H.,
and Cantley, L. C.
(1994)
Curr. Biol.
4,
973-982
|
| 65.
|
Wu, X.,
Ranganthan, V.,
Weisman, D. S.,
Heine, W. F.,
Ciccone, D. N.,
O'Neill, T. B.,
Crick, K. E.,
Pierce, K. A.,
Lane, W. S.,
Rathbun, G.,
Livingston, D. M.,
and Weaver, D. T.
(2000)
Nature
405,
477-482
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. C. Riches, A. M. Lynch, and N. J. Gooderham
Early events in the mammalian response to DNA double-strand breaks
Mutagenesis,
September 1, 2008;
23(5):
331 - 339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kulkarni and K. C. Das
Differential roles of ATR and ATM in p53, Chk1, and histone H2AX phosphorylation in response to hyperoxia: ATR-dependent ATM activation
Am J Physiol Lung Cell Mol Physiol,
May 1, 2008;
294(5):
L998 - L1006.
[Abstract]
[Full Text]
[PDF]
|
 |
|